Replies to post #210934 on Innovation Pharmaceuticals Inc (IPIX)

[georgejjl]

“As a result, therapies targeting p53 have long been pursued, highly sought-after by Big Pharma, but have largely been met with limited success due to the inherent complexity of p53. So, to see Kevetrin modulate p53 in a clinical setting in tumor biopsies from patients is an exciting moment for the Company, positioning us at the forefront of developing a potentially transformative anti-cancer therapy.”

http://www.ipharminc.com/press-release/2017/12/27/innovation-pharmaceuticals-obtains-direct-evidence-of-molecular-pathways-modulation-in-tumors-from-first-patients-in-kevetrin-ph2a-ovarian-cancer-trial

Good luck and GOD bless,

George

[xoc]

I just did further research on Advexin. It's initial company Introgen went bankrupt in 2009. Adam Fuerstein maintains that Advexin doesn't work and that it's executives made false promises to investors. He states the company is trying to make a comeback under the name Multivir. Multivir has an active phase 1 trial (clinical trial identifier: NCT02842125)of what is now called Ad-p53 ,in combination with Xeloda for patients with refractory liver metastasis from colorectal cancer and other solid tumors. This study started June 2016 with anticipated primary completion date July 2018. We are ahead of this drug in the race for the p53 holy grail.